Maria Luísa Cordeiro Santos

Maria Luísa Cordeiro Santos

Auto-generated profile, based on publicly available information

Maria Luísa Cordeiro Santos

Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Bahia, Brazil

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Expert Review of Vaccines
Verified
Journal Article
Closed access
IVIrineu Dos Santos Viana
Irineu Dos Santos Viana
MSMaria Luísa Cordeiro Santos
Maria Luísa Cordeiro Santos
HMHanna Santos Marques
Hanna Santos Marques
VGVinícius Lima de Souza Gonçalves
Vinícius Lima de Souza Gonçalves
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FMFabrício De melo
Fabrício De melo
Introduction: The interest of the world scientific community for an effective vaccine against Helicobacter pylori infection arises from its high prevalence and association with many diseases. Moreover, with an immunological response that is not always effective for the eradication of the bacteria and an increasing antibiotic resistance in the treatment of this infection, the search for a vaccine and new therapeutic modalities to control this infection is urgent. Areas covered: We bring an overview of the infection worldwide, discussing its prevalence, increasing resistance to antibiotics used in its therapy, in addition to the response of the immune system to the infection registered so far. Moreover, we address the most used antigens and their respective immunological responses expected or registered up to now. Finally, we address the trials and their partial results in development for such vaccines. Expert opinion: Although several studies for the development of an effective vaccine against this pathogen are taking place, many are still in the preclinical phase or even without updated information. In this sense, taking into account the high prevalence and association with important comorbidities, the interest of the pharmaceutical industry in developing an effective vaccine against this pathogen is questioned.

1 June 2004 in Journal Of Hypertension
Verified
Journal Article
Closed access
NJN. Jabary
N. Jabary
IFI. Fernandez
I. Fernandez
EGE. Gonzalez
E. Gonzalez
MMM. F. Muñoz
M. F. Muñoz
DMD. Martin
D. Martin
RGR. Gordillo
R. Gordillo